TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY FINAL REPORT AND RECOMMENDATIONS

Recommendations

Info

77 Dr. Reshma Ramachandran, Assistant Scientist, ReAct Strategic Policy Program, Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health Matthew J Renwick, Health Policy and Economics Researcher, London School of Economics and Political Science Dr. Julie Robotham, Modelling and Economics Lead, AMR and Hospital Acquired Infections, National Infection Service, Public Health England Professor H.M. Scott, Lecturer Veterinary Medicine and Biomedical Science, Texas A&M University Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health Dr. Katy Turner, Senior Lecturer, Infectious Diseases Epidemiology, University of Bristol Dr. Philip Turner, Researcher, NIHR Diagnostic Evidence Cooperative Oxford, Nuffield Department of Primary Care Health Sciences, University of Oxford Professor Ann Van den Bruel, Director, NIHR Diagnostic Evidence Cooperative Oxford, Nuffield Department of Primary Care Health Sciences, University of Oxford Dr. Anita Sharma, Regional Head, SRL Limited Dr. Anthony D. So, MD, MPA, Director, Center for a Livable Future and Coordinator, ReAct Strategic Policy Program, Lucas Wiarda, Global Marketing Director and Head of the Sustainable Antibiotics Program, DSM Sinochem Pharmaceuticals Sophia Wilkinson, Senior Health Adviser, BBC Media Action Finally, we would like to renew our acknowledgements of all those individuals and institutions who have contributed to our reports in the past as well as this final report. Mohadeseh Abdullahi, London School of Economics and Political Science James Anderson, Director, External Partnerships, GlaxoSmithKline Dr. Manica Balasegeram, Executive Director, Access Campaign, Médecins Sans Frontières Owen Barder, Head of the Center for Global Development, Europe Professor Peter Borriello, Chief Executive Officer, Veterinary Medicines Directorate, Department of Environment, Food and Rural Affairs, UK Dr. Helen Boucher, Director, Infectious Diseases Fellowship Program, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Centre, Associate Professor of Medicine, Tufts University School of Medicine, Boston, MA, USA Professor John Brownstein, Harvard Medical School, and Chief Innovation Officer, Boston Children's Hospital Tobias Broger, Technical Officer, Foundation for Innovative New Diagnostics Capstone Students from the London School of Economics and Political Science Neil Butler, Chief Executive Officer Spectromics Professor Otto Cars, Senior Professor, Infectious Diseases, Founder and Senior Adviser, ReAct-Action on Antibiotic Resistance, Uppsala University Dr. Charles Clift, Senior Consulting Fellow, Centre on Global Health Security, Chatham House Dr. Timothy Cooke, Chief Executive Officer, NovaDigm Therapeutics, Inc. Jane Coyne, Director of TB Programs, Office of the United Nations Special Envoy on Tuberculosis, University of California, San Francisco Matthew Brack, Project Manager, Centre on Global Health Security, Chatham House Dr. Val Curtis, Director, Environmental Health Group, London School of Hygiene and Tropical Medicine
78 Dr. Lloyd Czaplewski, Director, Chemical Biology Ventures Carla Deakin, Associate Director - Diagnostics Assessment Programme, National Institute for Health and Care Excellence (NICE) Dr. Kitty Healey, Head of Antimicrobial Resistance Team, Veterinary Medicines Directorate, Department of Environment, Food and Rural Affairs, UK The Health Protection Analytical Team, Department of Health Dr. Elisabeth Delarocque-Astagneau, Pharmacopepidemiology and Infectious Diseases, Insitut Pasteur Professor Carl Heneghan, Centre for Evidence-Based Medicine, Nuffield Department of Primary Care, University of Oxford Dr. Miles Denton, Lead Public Health Microbiologist, Public Health England Professor Aidan Hollis, Department of Economics, University of Calgary Professor David Denning, President of the Global Action Fund for Fungal Infections Professor Richard Holliman, Lead Public Health Microbiologist, Public Health England Staff of Department of Health, UK Staff at the Department of International Development Dr. Susan Hopkins, Consultant in Infectious Diseases & Microbiology, Royal Free London NHS Foundation Trust, and Healthcare Epidemiologist, Public Health England Professor Dilip Nathwani, Antimicrobial Research Centre, Academic Health Sciences Partnership in Tayside Professor Christopher Dowson, Professor of Microbiology at the University of Warwick Dr. Martin H. Friede, Programme Leader, Technology Transfer Initiative, World Health Organization Dr. Keith Fuglie, Structure, Technology and Productivity Branch in the Resource and Rural Economics Division, Economic Research Service, United States Department of Agriculture Bim Hundal, Partner, Lion’s Head Global Partners Dr. David Jenkins, Consultant Medical Microbiologist, University Hospitals of Leicester NHS Trust Dr. Elizabeth M. Johnson, Director, Mycology Reference Laboratory, National Infection Services, Public Health England Professor Stefan H.E. Kaufmann, Director, Max Planck Institute Dr. Nadia Khelef, Senior Advisor for Global Affairs, Institut Pasteur Dr. Keiji Fukuda, Special Representative for Antimicrobial Resistance in the office of the WHO Director-General Dr. Sue Kinn, Research Manager at Department for International Development Dr. William Gaze, The European Centre for Environment and Human Health, University of Exeter Medical School Dr. Klaus Kümmerer, Professor of Sustainable Chemistry and Resources, Leuphana University, Germany Dr. Bruce Gellin, Deputy Assistant Secretary for Health, Director, National Vaccine Program Office, United States Department of Health and Human Services Nicholas Gertler, Co-Founder at Galen/Atlantica Dr. Joe Larsen, Biomedial Advanced Research and Development (BARDA) Professor Joakim Larsson, Director, Centre for Antibiotic Resistance Research, University of Gothenburg Professor Herman Goossens, Professor of Medical Microbiology, University Hospital of Antwerp Dr. Helen Lee, Director of Research, Department of Haematology, Cambridge University Professor Kate Gould, Lead Public Health Microbiologist, Public Health England Professor Marc Lipsitch, Professor of Epidemiology, Harvard University
Page 1 and 2:
TACKLING DRUG-RESISTANT INFECTIONS
Page 3 and 4:
ACRONYMS AND ABBREVIATIONS AMC Adva
Page 5 and 6:
2 time focusing on this over the la
Page 7 and 8:
4 EXECUTIVE SUMMARY Following 19 mo
Page 9 and 10:
6 7. Improve the numbers, pay and r
Page 11 and 12:
8 Review on Antimicrobial Resistanc
Page 13 and 14:
10 1. THE PROBLEM: WHY TACKLING AMR
Page 15 and 16:
12 This challenge will only get wor
Page 17 and 18:
14 AMR-related research between 200
Page 19 and 20:
16 An outline of the market failure
Page 21 and 22:
18 LOWERING DEMAND FOR ANTIMICROBIA
Page 23 and 24:
20 Labelling of medicines and food:
Page 25 and 26:
22 BETTER WATER AND SANITATION REDU
Page 27 and 28:
24 Intervention 3: Reduce unnecessa
Page 29 and 30: 26 is an issue that the G20 must ta
Page 31 and 32: 28 HOW COUNTRIES COULD ACHIEVE TARG
Page 33 and 34: 30 Reduce Environmental pollution W
Page 35 and 36: 32 Intervention 4: Improve global s
Page 37 and 38: 34 data’ that will be generated a
Page 39 and 40: 36 RAPID DIAGNOSTICS WOULD REDUCE U
Page 41 and 42: 38 NEW RAPID DIAGNOSTICS WOULD OPTI
Page 43 and 44: 40 Intervention 6: Promote developm
Page 45 and 46: 42 ALTERNATIVE PRODUCTS TO TACKLE I
Page 47 and 48: 44 Intervention 7: Improve the numb
Page 49 and 50: 46 rising drug resistance as poorer
Page 51 and 52: 48 INCREASING THE SUPPLY OF ANTIMIC
Page 53 and 54: 50 critical to ensure that efforts
Page 55 and 56: 52 Intervention 9: Better incentive
Page 57 and 58: 54 to emerge more quickly than comm
Page 59 and 60: 56 investment decisions by companie
Page 61 and 62: 58 need to sit on top of and fit wi
Page 63 and 64: 60 Tuberculosis: a cornerstone of t
Page 65 and 66: 62 of a new diagnostic (with no new
Page 67 and 68: 64 4. HOW TO PAY FOR IT: TACKLING A
Page 69 and 70: 66 level, agreements between compan
Page 71 and 72: 68 3. Exchangeable ‘vouchers’ t
Page 73 and 74: 70 antimicrobials and do not incent
Page 75 and 76: IF NOT TACKLED, RISING AMR COULD HA
Page 77 and 78: 74 3.5 3.6 3.7 In 2018, defined tar
Page 79: 76 ACKNOWLEDGEMENTS The views and o
Page 83 and 84: 80 Dr. John Stelling, Co-Director o
show all

TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY FINAL REPORT AND RECOMMENDATIONS

Create successful ePaper yourself

Delete template?

Save as template?